Evidence brief · Supplement

Sarcosine for Schizophrenia (adjunct)

Evidence grade B — Add-on

Overall grade
Grade B
Last revised
1
graded outcome
0
references listed

Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.

1 at grade B — 1 graded row

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Schizophrenia (adjunct)Evidence grade B

    Add-on

    Smallmixed

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Studies disagree: Schizophrenia (adjunct) (mixed agreement).

The evidence in words

The verdict

For schizophrenia (adjunct), Sarcosine earns evidence grade B (small effect, mixed consistency) — there is real evidence here. Add-on

How it might work

It inhibits the glycine transporter (GlyT1), raising synaptic glycine and boosting NMDA-receptor function — the opposite of ketamine's NMDA blockade.

How to use it

Safety & cautions

Generally well tolerated; should not replace prescribed treatment, and NMDA modulation warrants clinical oversight in psychiatric illness.

Bottom line

A mechanistically interesting NMDA-enhancing amino acid with real (if small) adjunct evidence in schizophrenia — a clinical adjunct, not a casual nootropic.

Goes with

  • SarcosineRead the full Sarcosine monographEvidence grade C

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.

Last revised . A grade is this entry's reading of the evidence, not medical advice.